公开(公告)号：US20050244470A1

公开(公告)日：2005-11-03

申请号：US10837361

申请日：2004-04-30

申请人： Patrick Hughes ,  Thomas Malone ,  Gerald De Vries ,  Jeffrey Edelman ,  Joan-En Chang-Lin ,  Jane Shiah ,  Thierry Nivaggioli

发明人： Patrick Hughes ,  Thomas Malone ,  Gerald De Vries ,  Jeffrey Edelman ,  Joan-En Chang-Lin ,  Jane Shiah ,  Thierry Nivaggioli

IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K31/00 ,  A61K31/404 ,  A61F2/00

CPC分类号： A61K9/0051 ,  A61K9/1647 ,  Y10T428/2985

摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

摘要翻译： 生物相容性眼内植入物包括酪氨酸激酶抑制剂和生物可降解聚合物，其有效促进酪氨酸激酶抑制剂长时间释放到眼睛中。 植入物的治疗剂可以与可生物降解的聚合物基质相关，例如基本上不含聚乙烯醇的基质。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生。

公开(公告)号：US20070059336A1

公开(公告)日：2007-03-15

申请号：US11364687

申请日：2006-02-27

申请人： Patrick Hughes ,  Thomas Malone ,  Gerald De Vries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

发明人： Patrick Hughes ,  Thomas Malone ,  Gerald De Vries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

IPC分类号： A61K38/18 ,  A61K39/395

CPC分类号： A61K48/0041 ,  A61K9/0051

摘要： Biocompatible intraocular drug delivery systems include a anti-angiogenic therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis peptides, hormones and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

摘要翻译： 生物相容性眼内药物递送系统包括抗血管生成治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三维结构，但保持其治疗活性。 治疗剂可以选自抗血管生成肽，激素和核酸试剂。 植入物可以置于眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。